Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-28.e2. https://doi.org/10.1016/j.anai.2020.12.020.

Article  PubMed  Google Scholar 

Al Shobaili HA. The impact of childhood atopic dermatitis on the patients’ family. Pediatr Dermatol. 2010;27(6):618–23. https://doi.org/10.1111/j.1525-1470.2010.01215.x.

Article  PubMed  Google Scholar 

Chamlin SL, Chren M-M. Quality-of-life outcomes and measurement in childhood atopic dermatitis. Immunol Allergy Clin North Am. 2010;30(3):281–8. https://doi.org/10.1016/j.iac.2010.05.004.

Article  PubMed  PubMed Central  Google Scholar 

Eyerich K, Gooderham MJ, Silvestre JF, et al. Real-world clinical, psychosocial, and economic burden of atopic dermatitis: results from a multicountry study. J Eur Acad Dermatol Venereol. 2023. https://doi.org/10.1111/jdv.19500.

Article  PubMed  Google Scholar 

Knudgaard MH, Andreasen TH, Ravnborg N, et al. Rhinitis prevalence and association with atopic dermatitis: a systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2021;127(1):49-56.e1. https://doi.org/10.1016/j.anai.2021.02.026.

Article  PubMed  Google Scholar 

Ravnborg N, Ambikaibalan D, Agnihotri G, et al. Prevalence of asthma in patients with atopic dermatitis: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(2):471–8. https://doi.org/10.1016/j.jaad.2020.02.055.

Article  PubMed  Google Scholar 

Tsakok T, Marrs T, Mohsin M, et al. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol. 2016;137(4):1071–8. https://doi.org/10.1016/j.jaci.2015.10.049.

Article  PubMed  Google Scholar 

Paller AS, Mina-Osorio P, Vekeman F, et al. Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: real-world evidence. J Am Acad Dermatol. 2022;86(4):758–65. https://doi.org/10.1016/j.jaad.2021.10.038.

Article  PubMed  Google Scholar 

Paller AS, Spergel JM, Mina-Osorio P, Irvine AD. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46–55.

Article  PubMed  Google Scholar 

Van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol. 2007;120(3):565–9.

Article  PubMed  Google Scholar 

Aberle N, Kljaić Bukvić B, Blekić M, et al. Allergic diseases and atopy among schoolchildren in eastern Croatia. Acta Clin Croat. 2018;7(1):82–90. https://doi.org/10.1016/j.jaad.2007.06.041.

Article  Google Scholar 

Kapoor R, Menon C, Hoffstad O, et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol. 2008;58(1):68–73. https://doi.org/10.1016/j.jaad.2007.06.041.

Article  PubMed  Google Scholar 

Bergmann MM, Caubet JC, Boguniewicz M, Eigenmann PA. Evaluation of food allergy in patients with atopic dermatitis. J Allergy Clin Immunol Pract. 2013;1(1):22–8. https://doi.org/10.1016/j.jaip.2012.11.005.

Article  PubMed  Google Scholar 

Breuer K, Heratizadeh A, Wulf A, et al. Late eczematous reactions to food in children with atopic dermatitis. Clin Exp Allergy. 2004;34(5):817–24. https://doi.org/10.1111/j.1365-2222.2004.1953.x.

Article  CAS  PubMed  Google Scholar 

Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Pediatr. 1985;107(5):669–75. https://doi.org/10.1016/s0022-3476(85)80390-5.

Article  CAS  PubMed  Google Scholar 

Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–37. https://doi.org/10.1080/1744666X.2017.1298443.

Article  CAS  PubMed  Google Scholar 

Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA. 2014;111(14):5147–52. https://doi.org/10.1073/pnas.1323896111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA. 2014;111(14):5153–8. https://doi.org/10.1073/pnas.1324022111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–204. https://doi.org/10.1111/all.14151.

Article  CAS  PubMed  Google Scholar 

Regeneron Pharmaceuticals, Inc./sanofi-aventis U.S. LLC. Highlights of Prescribing Information. In: DUPIXENT® (dupilumab) injection, for subcutaneous use. US Food and Drug Administration. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s040lbl.pdf. Accessed Nov 25, 2023.

Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–9. https://doi.org/10.1056/NEJMoa1314768.

Article  CAS  PubMed  Google Scholar 

Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52. https://doi.org/10.1016/S0140-6736(15)00388-8.

Article  CAS  PubMed  Google Scholar 

Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48. https://doi.org/10.1056/NEJMoa1610020.

Article  CAS  PubMed  Google Scholar 

Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–303. https://doi.org/10.1016/S0140-6736(17)31191-1.

Article  CAS  PubMed  Google Scholar 

de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–101. https://doi.org/10.1111/bjd.16156.

Article  CAS  PubMed  Google Scholar 

Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908–19. https://doi.org/10.1016/S0140-6736(22)01539-2.

Article  CAS  PubMed  Google Scholar 

Boguniewicz M, Beck LA, Sher L, et al. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021;9(3):1212-23.e6. https://doi.org/10.1016/j.jaip.2020.12.059.

Article  PubMed  Google Scholar 

Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56. https://doi.org/10.1001/jamadermatol.2019.3336.

Article  PubMed  Google Scholar 

Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–93. https://doi.org/10.1016/j.jaad.2020.06.054.

Article  CAS  PubMed  Google Scholar 

Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020;182(1):85–96. https://doi.org/10.1111/bjd.18476.

Article  CAS